From: Emerging agents and regimens for hepatocellular carcinoma
Combinations | Number of patients | ORR (RECIST v1.1) | Median PFS (months) | Grade 3/4 AE | Reference |
---|---|---|---|---|---|
Apatinib + camrelizumab | 16 (second line) | 50% | 5.8 | NA | Xu et al. [54] |
Lenvatinib + pembrolizumab | 30 (26/30 as first line) | 53.3% | 9.7 | NA | Kudo [81] |
Bevacizumab + atezolizumab | 68 (first line) | 34% | 14.9 | 25% | Pishvaian et al. [82] |
Durvalumab + tremelimumab | 40 (first and second line) | 25% | NA | 25% | Kelley et al. [83] |
Ipilimumab + nivolumab | 148 (second line) | 31% | NA | 37% | Yau et al. [65] |
Axitinib + avelumab | 22 (first line) | 13.6% | 5.5 | 72.7% | Kudo et al. [84] |
FOLFOX4 + camrelizumab | 34 (first line) | 26.5% | 5.5 | 5.9% | Qin et al. [85] |